Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132903) titled 'Two novel TRPC6 variants in familial focal segmental glomerulosclerosis prolong receptor-evoked calcium signalling' on Sept. 20.
Study Type: Observational study
Study Design:
Case study
Primary Sponsor: Zhejiang Provincial People's Hospital
Condition:
Chronic kidney disease with a TRPC6 mutation
histopathology consistent with FSGS
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-09-30
Target Sample Size: Patients with TRPC6 mutations:2;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=341062
Published by HT Digital Conten...